Active AML Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Acute Myeloid Leukemia (AML) Clinical Trial?

• Find Trials That Fit — Browse recruiting Acute Myeloid Leukemia (AML) trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Acute Myeloid Leukemia (AML) type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Acute Myeloid Leukemia (AML) Clinical Trial FAQ

What genetic mutations matter most for AML clinical trial eligibility?

Key actionable mutations in AML include: FLT3-ITD and FLT3-TKD (targeted by midostaurin, gilteritinib, quizartinib), IDH1 (targeted by ivosidenib), IDH2 (targeted by enasidenib), NPM1 (marker for prognosis and MRD monitoring), CEBPA (favorable prognosis), TP53 (poor prognosis; trials testing novel p53-targeting agents), and core binding factor AML (inv(16), t(8;21)). Comprehensive cytogenetic and molecular testing is essential before choosing a trial.

Are there AML trials for older patients who cannot receive intensive chemotherapy?

Yes — this is one of the most important areas of AML research. Venetoclax (BCL-2 inhibitor) plus azacitidine or decitabine is FDA-approved for older or unfit AML patients. Trials are testing venetoclax combinations with novel targeted agents, lower-intensity regimens designed for older adults, and oral therapy options. The goal is improving outcomes while minimizing toxicity.

What is MRD (minimal residual disease), and does it affect AML trial eligibility?

MRD refers to small amounts of leukemia cells remaining after treatment that are below the threshold of standard tests. MRD negativity (undetectable residual disease) is a powerful prognostic marker in AML. Some trials specifically enroll MRD-positive patients in remission (to prevent relapse), while others use MRD as a response endpoint. Knowing your MRD status after initial treatment is increasingly important for trial planning.

Do I need to consider a stem cell transplant before or instead of an AML trial?

Stem cell transplant remains an important part of AML treatment for many patients, particularly those with intermediate or adverse-risk disease. The relationship between transplant and trial participation is complex — some trials are designed for patients who are transplant candidates, others for transplant-ineligible patients, and some test novel consolidation strategies after transplant. Your hematologist can help decide the right sequencing.

How do I find an AML trial quickly given how fast the disease progresses?

AML progresses rapidly and treatment decisions must often be made within days of diagnosis. Trialify can help you identify matching trials immediately based on your mutation profile and prior treatment status. Bringing a list of your cytogenetic and molecular results to your first hematology appointment, along with trial options identified on Trialify, will allow your doctor to make faster decisions.

Explore Other Cancer Trial Guides

• Leukemia — Leukemia trials are testing targeted inhibitors, CAR-T therapies, and novel transplant strategies for AML, ALL, CLL, and CML. New treatment options are emerging rapidly across all leukemia types.
• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.
• Multiple Myeloma — Multiple myeloma trials are advancing CAR-T therapies, bispecific antibodies, BCMA-targeted agents, and novel triplet combinations — offering new paths for newly diagnosed and relapsed/refractory patients.
• Ovarian Cancer — Ovarian cancer trials are investigating PARP inhibitor combinations, antibody-drug conjugates, folate receptor-targeted therapy, and immunotherapy — with studies available for both platinum-sensitive and resistant disease.